{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:29:58Z","timestamp":1759991398985},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Clin. Microbiol. Infect. Dis."],"published-print":{"date-parts":[[1998,6]]},"DOI":"10.1007\/bf01691580","type":"journal-article","created":{"date-parts":[[2005,5,15]],"date-time":"2005-05-15T02:50:19Z","timestamp":1116125419000},"page":"441-446","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study"],"prefix":"10.1007","volume":"17","author":[{"given":"B.","family":"O'Doherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Trovafloxacin Bronchitis Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01691580_CR1","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1358\/dof.1996.021.05.356026","volume":"21","author":"RA Fromtling","year":"1996","unstructured":"Fromtling RA, Casta\u00f1er J: Trovafloxacin mesylate. Drugs of the Future (1996) 21:496\u2013505","journal-title":"Drugs of the Future"},{"key":"BF01691580_CR2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W","volume":"16","author":"TD Gootz","year":"1996","unstructured":"Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews (1996) 16:433\u2013486","journal-title":"Medicinal Research Reviews"},{"key":"BF01691580_CR3","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jac\/36.5.873","volume":"36","author":"KP Klugman","year":"1995","unstructured":"Klugman KP, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and-resistantStreptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:878\u2013880","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691580_CR4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jac\/35.1.230","volume":"35","author":"GA Pankuch","year":"1995","unstructured":"Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230\u2013232","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"Supplement 2","key":"BF01691580_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/00003495-199500492-00043","volume":"49","author":"RN Jones","year":"1995","unstructured":"Jones RN: In vitro antimicrobial activity of CP-99,219, a new 7-azabicylonaphthyridone. Drugs (1995) 49, Supplement 2:205\u2013207","journal-title":"Drugs"},{"key":"BF01691580_CR6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/BF01691164","volume":"15","author":"F Crokaert","year":"1996","unstructured":"Crokaert F, Aoun M, Duchateau V, Grenier P, Rossi C, Vandermies A, Klastersky J: In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:696\u2013698","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"key":"BF01691580_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/36.2.385","volume":"36","author":"R Teng","year":"1995","unstructured":"Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE: Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy (1995) 36:385\u2013394","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691580_CR8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jac\/37.5.955","volume":"37","author":"R Teng","year":"1996","unstructured":"Teng R, Liston TE, Harris SC: Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy (1996) 37:955\u2013963","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"BF01691580_CR9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/0003-4819-106-2-196","volume":"106","author":"NR Anthonisen","year":"1987","unstructured":"Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine (1987) 106:196\u2013204","journal-title":"Annals of Internal Medicine"},{"key":"BF01691580_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/0003-4819-97-1-18","volume":"97","author":"MB Nicotra","year":"1982","unstructured":"Nicotra MB, Rivera M, Awe RJ: Antibiotic therapy of acute exacerbation of chronic bronchitis. Annals of Internal Medicine (1982) 97:18\u201320","journal-title":"Annals of Internal Medicine"},{"key":"BF01691580_CR11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-97-1-130","volume":"97","author":"JM Bates","year":"1982","unstructured":"Bates JM: The role of infection during exacerbation of chronic bronchitis. Annals of Internal Medicine (1982) 97:130\u2013131","journal-title":"Annals of Internal Medicine"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01691580.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01691580\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01691580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T16:00:35Z","timestamp":1557244835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01691580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["BF01691580"],"URL":"https:\/\/doi.org\/10.1007\/bf01691580","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}